Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective cohort study of Walrinvax (domestic bivalent HPV vaccine) effectiveness in 18–30-year-old women
CTR20233692Phase 4Active
- Sponsor
- Yuxi Zerun Biotechnology Co., Ltd.
- Start
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of human papillomavirus 16/18 bivalent vaccine in Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN), cervical adenocarcinoma, HPV16 infection (HPV16), human papillomavirus infection type 18, sponsored by Yuxi Zerun Biotechnology Co., Ltd.. Started Nov 2023; status: active.
02
Drugs
human papillomavirus 16/18 bivalent vaccine
03
Conditions
Cervical Cancer (CC)cervical intraepithelial neoplasia (CIN)cervical adenocarcinomaHPV16 infection (HPV16)human papillomavirus infection type 18
Beyond the preview
Go deeper on CTR20233692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233692.